High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units

被引:12
|
作者
Khan, Qasim [1 ,2 ]
Ismail, Mohammad [1 ]
Haider, Iqbal [3 ]
机构
[1] Univ Peshawar, Dept Pharm, Peshawar, Pakistan
[2] COMSATS Inst Informat Technol, Dept Pharm, Abbottabad, Pakistan
[3] Khyber Teaching Hosp, Dept Med, Peshawar, Pakistan
关键词
QT prolongation; torsades de pointes; QT prolonging drugs; coronary care unit; QT prolonging drug-drug interactions; TORSADES-DE-POINTES; ACADEMIC-MEDICAL-CENTER; PROLONGING DRUGS; LONG QT; FREQUENCY; US;
D O I
10.1080/00325481.2018.1516106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Patients admitted in coronary care units are susceptible to QT interval prolongation due to numerous risk factors. The purpose of this study was to identify the prevalence of risk factors for QT interval prolongation; QT prolonging medications; drug-drug interactions; their predictors; and torsades de pointes risks of drugs. Methods: After obtaining approval, this cross-sectional study was carried out during one-year period in coronary care units of two major tertiary care hospitals of Khyber Pakhtunkhwa, Pakistan. The Arizona Center for Education and Research on Therapeutics QT drugs lists and Micromedex DrugReax (R) were used to identify the QT prolonging medications and QT prolonging drug-drug interactions. Results: Total 649 patients were included in this study. The most frequent QT prolonging risk factors included use of >= 1 QT prolonging drugs (74.9%) and myocardial infarction (61.3%). Total 181 patients were presented with 361 QT prolonging drug-drug interactions. There was significant association of the occurrence of QT prolonging drug-drug interactions with female gender (p = 0.01), 9-10 prescribed medications (p = 0.001), and > 10 prescribed medications (p < 0.001). Conclusions: The majority of patients presented with multiple risk factors for QT prolongation in coronary care units which may precipitate lethal outcomes.
引用
收藏
页码:660 / 665
页数:6
相关论文
共 50 条
  • [41] Prevalence, Levels and Association With Risk Factors Potential Drug-Drug Interactions in Outpatient General Medicine Ward of a Tertiary Care Hospital
    Ghosh, Sourav
    Jana, S.
    Krishnaveni, K.
    Anila, K. N.
    Goli, D.
    INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 : S193 - S193
  • [42] Prevalence, Levels and Association With Risk Factors of Potential Drug-Drug Interactions in Inpatient General Medicine Ward of a Tertiary Care Hospital
    Jana, Shatabdi
    Ghosh, S.
    Krishnaveni, K.
    Anila, K. N.
    Goli, D.
    INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 : S195 - S195
  • [43] Drug-drug interactions in Neonatal Intensive Care Units: how to overcome a challenge
    Rosen, Kai
    Wiesen, Martin H.
    Oberthuer, Andre
    Michels, Guido
    Roth, Bernd
    Fietz, Cornelia
    Mueller, Carsten
    MINERVA PEDIATRICS, 2021, 73 (02): : 188 - 197
  • [44] A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation
    Simon, Steven T.
    Lin, Meng
    Trinkley, Katy E.
    Aleong, Ryan
    Rafaels, Nicholas
    Crooks, Kristy R.
    Reiter, Michael J.
    Gignoux, Christopher R.
    Rosenberg, Michael A.
    PLOS ONE, 2024, 19 (06):
  • [45] Prevalence and Risk Factors for Osimertinib-associated Drug-Drug Interactions in Non-small-cell Lung Cancer Patients
    Rong, Li
    Qiu, Hongyu
    Xie, Mengyuan
    Zhao, Ziqi
    Wei, Taotao
    Dai, Anqi
    Liu, Chengke
    Zhang, Saiyu
    Kong, Lingti
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1612 - 1617
  • [46] Prevalence of Polypharmacy and Potential Drug-Drug Interactions Associated with Risk Factors in the Era of HIV Integrase Inhibitors: A Prospective Clinical Study
    Altunal, Lutfiye Nilsun
    Caglayik, Dilek Yagci
    Ozel, Ayse Serra
    Tigen, Elif Tukenmez
    Sili, Uluhan
    Sengel, Buket Erturk
    Aydin, Mehtap
    Korten, Volkan
    AIDS PATIENT CARE AND STDS, 2023, 37 (03) : 138 - 145
  • [47] Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice
    Florine A. Berger
    Heleen van der Sijs
    Matthijs L. Becker
    Teun van Gelder
    Patricia M. L. A. van den Bemt
    BMC Medical Informatics and Decision Making, 20
  • [48] Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice
    Berger, Florine A.
    van der Sijs, Heleen
    Becker, Matthijs L.
    van Gelder, Teun
    van den Bemt, Patricia M. L. A.
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2020, 20 (01)
  • [49] Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care
    M. L. Andersson
    Y. Böttiger
    J. D. Lindh
    B. Wettermark
    B. Eiermann
    European Journal of Clinical Pharmacology, 2013, 69 : 565 - 571
  • [50] Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis
    Ramasubbu, Saravana Kumar
    Mishra, Archana
    Mandal, Soumitra
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (01) : 162 - 168